ReviewJournal of clinical medicine research2019
Updates in Treatment of Recurrent
Review in Journal of clinical medicine research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI.BMC infectious diseases · 2021Pooled it
- Review
- Whole-genome characteristics of isolates from recurrentMicrobiology spectrum · 2026Article
- Observational
- Epidemiology and Course of Clostridioides difficile Infections in Germany: Retrospective Analysis of German Health Claims Data.Infectious diseases and therapy · 2025Article
- Review
- The Global Burden ofInfectious disease reports · 2025Review
- Loratadine as an Anti-inflammatory Agent Against Clostridium difficile Toxin B.The Journal of infectious diseases · 2024Article
- Observational
- PhosphoLipidome Alteration Induced byCells · 2024Article
- A Systematic Literature Review on Risk Factors for and Timing of Clostridioides difficile Infection in the United States.Infectious diseases and therapy · 2024Review
- Host-defense piscidin peptides as antibiotic adjuvants against Clostridioides difficile.PloS one · 2024Article
- Fecal Microbiota Transplantation as Emerging Treatment in European Countries 2.0.Advances in experimental medicine and biology · 2024Review
- Article
- The microbial-derived bile acid lithocholate and its epimers inhibitJournal of bacteriology · 2023Article
- Review
- Host Immunity and Immunization Strategies for Clostridioides difficile Infection.Clinical microbiology reviews · 2023Review
- Effects of Omeprazole on Recurrent Clostridioides difficile Infection Caused by ST81 Strains and Their Potential Mechanisms.Antimicrobial agents and chemotherapy · 2023Article
- The microbial derived bile acid lithocholate and its epimers inhibitbioRxiv : the preprint server for biology · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.